Suppression of hepatoma growth and angiogenesis by a fumagillin derivative TNP470: Possible involvement of nitric oxide synthase

Cancer Research

Volumn 58, Issue 16, 1998, Pages 3751-3756

  Yoshida, Taku ^a   Kaneko, Yoshiyasu ^a   Tsukamoto, Ayumi ^a   Han, Katsuken ^a   Ichinose, Masao ^a   Kimura, Satoshi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; FUMAGILLOL CHLOROACETYLCARBAMATE; LEUKEMIA INHIBITORY FACTOR; N ACETYL S NITROSOPENICILLAMINE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE;

ANGIOGENESIS; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CACHEXIA; CANCER INHIBITION; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; LIVER CELL CARCINOMA; MOUSE; MYRISTYLATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENESCENCE; SUBCUTANEOUS DRUG ADMINISTRATION; TUMOR VOLUME; VASCULAR ENDOTHELIUM;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; BETA-GALACTOSIDASE; CARCINOMA, HEPATOCELLULAR; CATTLE; CELL DIVISION; CELL MOVEMENT; CYCLOHEXANES; ENDOTHELIAL GROWTH FACTORS; ENDOTHELIUM, VASCULAR; HUMANS; LIVER NEOPLASMS; LYMPHOKINES; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; SESQUITERPENES; TRANSPLANTATION, HETEROLOGOUS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS; WEIGHT LOSS;

EID: 0032529455     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Hanahan, D., and Folkman, J. Pattern and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell, 86: 353-364, 1996.
2. Weinstat-Saslow, D. L., Zabrenetzky, D. D., and Steeg, P. S. Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis. Cancer Res., 54: 6504-6511, 1994.
3. Bouck, N., Stellmach, V., and Hsu, S. C. How tumors become angiogenic. Adv. Cancer Res., 69: 135-174, 1996.
4. O'Reilly, M. S., Holmgren, L., Chen, C., and Folkman, L. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat. Med., 2: 689-692, 1996.
5. Ziche, M., Morbidelli, L., Masini, E., Amerini, S., and Ledda, F. Nitric oxide mediates angiogenesis in vivo and endothelial cell growth and migration in vitro by substance P. J. Clin. Invest., 94: 2036-2044, 1994.
6. Jenkins, D. C., Charles, I. G., Thompson, L. L., Rhodes, P., Westmore, K., Emson, P. C., and Moncada, S. Role of nitric oxide in tumor angiogenesis. Proc. Natl. Acad. Sci. USA, 92: 4392-4396, 1995.
7. Ingber, D., Fujita, T., Kishimoto, S., Sudo, K., Kanamaru, T., Brem, H., and Folkman, J. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumor growth. Nature (London), 348: 555-557, 1990.
8. Parangi, S., O'Reilly M., Christofori, G., Holmgren, L., Grosfeld, J., Folkman, J., and Hanahan, D. Antiangiogenic therapy of transgenic mice impairs de novo tumor growth. Proc. Natl. Acad. Sci. USA, 93: 2002-2007, 1996.
9. Koyama, H., Nishizawa, Y., Hosoi, M., Fukumoto, S., Kogawa, K., Shioi, A., and Morii, H. The fumagillin analogue TNP470 inhibits DNA synthesis of vascular smooth muscle cells stimulated by platelet-derived growth factor and insulin-like growth factor-1. Possible involvement of cyclin-dependent kinase 2. Circ. Res., 9: 754-764, 1996.
10. Abe, J., Zhou, W., Takuwa, N., Taguchi, J., Kurokawa, K., Kumada, M., and Takuwa, Y. A fumagillin derivative angiogenesis inhibitor, AGM-1470, inhibits activation of cyclin-dependent kinases and phosphorylation of retinoblastoma gene product but not protein tyrosyl phosphorylation or protooncogene expression in vascular endothelial cells. Cancer Res., 54: 3407-3412, 1994.
11. Sakoda, T., Hirata, K., Kuroda, R., Miki, N., Suematsu, M., Kawashima, S., and Yokoyama, M. Myristoylation of endothelial cell nitric oxide synthase is important for extracellular release of nitric oxide. Mol. Cell. Biochem., 152: 143-148, 1995.
12. Sin, N., Meng, L., Wang, M. Q. W., Wen, J. J., Bommann, W. G., and Crews, C. M. The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2. Proc. Natl. Acad. Sci. USA, 94: 6099-6103, 1997.
13. Griffith, E. C., Su, Z., Turk, B. E., Chen, S., Cheng, Y. H., Wu, Z., Biemann, K., and Liu, J. O. Methionine aminotransferase (type 2) is the common target for angiogenesis inhibitor AGM-a470 and ovalicin. Chem. Biol., 4: 461-471, 1997.
14. Ray-Chaudhury, A., Frischer, H., and Malik, A. B. Inhibition of endothelial cell proliferation and βFGF-induced phenotypic modulation by nitric oxide. J. Cell. Biochem., 63: 125-134, 1996.
15. Kaneko, Y., Tsukamoto, A., and Kurokawa, K. Vacuole formation and cytokeratin rearrangement of hepatoma cells induced by teleocidin are not associated with down-regulation of protein kinase C. Cancer Res., 51: 2677-2682, 1991.
16. Voyta, J. C., Via, D. P., Butterfield, C. E., and Zetter, B. R. Identification and isolation of endothelial cells based on their increased uptake of acetylated-low density lipoprotein. J. Cell Biol., 99: 2034-2040, 1984.
17. Arbiser, J. L., Mose, M. A., Fernandez, C. A., Ghiso, N., Cao, Y., Klauber, N., Frank, D., Brownlee, M., Flynn, E., Parangi, S., Byers, H. R., and Folkman, J. Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways. Proc. Natl. Acad. Sci. USA, 94: 861-866, 1997.
18. Fox, S. B., Leek, R. D., Weekes, M. P., Whitehouse, R. M., Gatter, K. C., and Harris, A. L. Quantitation and prognostic value of breast cancer angiogenesis: comparison of microvessel density, Chalkley count, and computer image analysis. J. Pathol., 177: 275-283, 1995.
19. Leek, R. D., Lewis, C. E., Whitehouse, R., Greenall, M., Clarke, J., and Harris, A. L. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res., 56: 4625-4629, 1996.
20. Piazza, G. A., Rahm, A. K., Finn, T. S., Fryer, B. H., Li, H., Stoumen, A. L., Pamukcu, R., and Ahnen, D. J. Apoptosis primary accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenese inhibition, cell cycle arrest, and p53 induction. Cancer Res., 57: 2452-2459, 1997.
21. Kaneko, Y., and Tsukamoto, A. Apoptosis and nuclear levels of p53 protein and proliferating cell nuclear antigen in human hepatoma cells cultured with tumor promoters. Cancer Lett., 91: 11-17, 1995.
22. Dimri, G. P., Lee, X., Basile, G., Acosta, M., Scott, G., Roskelley, C., Medranos, E. E., Linskens, M., Rubelj, I., Pereira-Smith, O., Peacocke, M., and Campisi, J. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl. Acad. Sci. USA, 92: 9363-9367, 1995.
23. 15N]nitrate in biological fluids. Anal. Biochem., 126: 131-138, 1982.
24. Pollack, J. S., Nakane, M., Buttery, L. D. K., Martinez, A., Springall, D., Polak, J. M., Förstermann, U., and Murad, F. Characterization and localization of endothelial nitric oxide synthase using specific monoclonal antibodies. Am. J. Physiol., 265: C1379-C11387, 1993.
25. Chen, B. E., and Knowles, B. R. A solvent system for delipidation of plasma or serum without protein precipitation. J. Lipid Res., 17: 176-181, 1976.
26. Ferrara, N., Houck, K., Jakeman, L., and Leung, D. W. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endoc. Rev., 13: 18-32, 1992.
27. Grugel, S., Finkenzeller, G., Weindel, K., Barleon, B., and Marme, D. Both v-Ha-ras and v-raf stimulate expression of the vascular endothelial growth factor in NIH3T3 cells. J. Biol. Chem., 270: 25915-25919, 1995.
28. Mon, M., Yamaguchi, K., Honda, S., Nagasaki, K., Ueda, M., Abe, O., and Abe, K. Cancer cachexia syndrome developed in nude mice bearing melanoma cells producing leukemia inhibitory factor. Cancer Res., 51: 6656-6659, 1991.
29. Pepper, M. S., Ferrara, N., Orci, L., and Montesano, R. Leukemia inhibitory factor (LIF) inhibits angiogenesis in vitro. J. Cell Sci., 108: 73-83, 1995.
30. Todorov, P., Cariuk, P., McDevitt, T., Coles, B., Fearon, K., and Tisdale, M. Characterization of a cancer cachexia factor. Nature (Lond.), 379: 739-742, 1996.
31. Chin, K., Kurashima, Y., Ogura, T., Tajiri, H., Yoshida, S., and Esumi, H. Induction of vascular endothelial growth factor by nitric oxide in human glioblastoma and hepatocellular carcinoma cells. Oncogene, 75: 437-442, 1997.
32. Ho, Y. S., Wang, Y. J., and Lin, J. K. Induction of p53 and p21/WAF1/CPIP1 expression by nitric oxide and their association with apoptosis in human cancer cells. Mol. Carcinog., 16: 20-31, 1996.
33. Kurose, I., Ebinuma, H., Higashi, H., Yonei, Y., Saito, H., Kato, S., Miura, S., and Ishii, H. Nitric oxide mediates nutochondrial dysfunction in hepatoma cells induced by non-activated Kuppffer cells: evidence implicating ICAM-1-dependent process. J. Gastroenterol. Hepatol., 10 (Suppl. 1): s68-s71, 1995.
34. Moriyama, A., Masumoto, A., Nanri, H., Tabaru, A., Unoki, H., Imoto, I., Ikeda, M., and Otsuki, M. High plasma concentrations of nitrite/nitrate in patients with hepatocellular carcinoma. Am. J. Gastroenterol., 92: 1520-1523, 1997.
35. Buss, J. E., Solski, P. A., Schaeffer, J. P., MacDonald, M. J., and Der, C. J. Activation of the cellular proto-oncogene product p21 Ras by addition of a myristoylation signal. Science (Washington DC), 243: 1600-1603, 1988.